Source: European Medicines Agency (EU) Revision Year: 2020 Publisher: Shire Pharmaceuticals Ireland Limited, Blocks 2 & 3 Miesian Plaza, 50-58 Baggot Street Lower, Dublin 2, Ireland, Tel: +44(0)1256 894 959, E-mail: medinfoEMEA@shire.com
TAKHZYRO 300 mg solution for injection.
| Pharmaceutical Form |
|---|
|
Solution for injection. The solution is colourless to slightly yellow, appearing either clear or slightly opalescent. The solution has a pH of approximately 6.0 and an osmolality of approximately 300 mOsm/kg. |
One vial contains 300 mg of lanadelumab* in 2 mL solution.
* Lanadelumab is produced in Chinese Hamster Ovary (CHO) cells by recombinant DNA technology.
For the full list of excipients, see section 6.1.
| Active Ingredient | Description | |
|---|---|---|
| Lanadelumab |
Lanadelumab is a fully human, monoclonal antibody (IgG1/Îș-light chain). Lanadelumab inhibits active plasma kallikrein proteolytic activity. Lanadelumab provides sustained control of plasma kallikrein activity and thereby limits bradykinin generation in patients with HAE. |
| List of Excipients |
|---|
|
Disodium phosphate dihydrate |
2 ml of solution in a vial (type I glass) with a coated butyl rubber stopper and an aluminium seal with violet flip-off cap.
TAKHZYRO is available as a single pack containing one 2 ml vial and in multipacks comprising 2 or 6 cartons, each carton containing 1 vial.
Not all pack sizes may be marketed.
Each pack also contains the following items:
Shire Pharmaceuticals Ireland Limited, Blocks 2 & 3 Miesian Plaza, 50-58 Baggot Street Lower, Dublin 2, Ireland, Tel: +44(0)1256 894 959, E-mail: medinfoEMEA@shire.com
EU/1/18/1340/001
EU/1/18/1340/002
EU/1/18/1340/003
Date of first authorisation: 22 November 2018
| Drug | Countries | |
|---|---|---|
| TAKHZYRO | Austria, Brazil, Canada, Estonia, Spain, Finland, France, Hong Kong, Croatia, Ireland, Israel, Italy, Japan, Lithuania, Netherlands, New Zealand, Poland, Romania, Turkey, United Kingdom, United States |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
